NCT00006026View on ClinicalTrials.gov

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

October 31, 2001

Conditions
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Interventions
DRUG

rubitecan

Trial Locations (11)

21079

Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon

28041

Hospital Universitario 12 de Octubre, Madrid

31096

Rambam Medical Center, Haifa

35128

Azienda Ospedaliera di Padova, Padova (Padua)

44805

CRLCC Nantes - Atlantique, Nantes-Saint Herblain

63011

Centre Jean Perrin, Clermont-Ferrand

76038

Centre Henri Becquerel, Rouen

B-3000

U.Z. Gasthuisberg, Leuven

3075 EA

Rotterdam Cancer Institute, Rotterdam

CH-6500

Ospedale San Giovanni, Bellinzona

Ch-1272

Clinique De Genolier, Genolier

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00006026 - Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract | Biotech Hunter | Biotech Hunter